Difference between revisions of "Tuberous sclerosis"

From Libre Pathology
Jump to navigation Jump to search
Line 10: Line 10:
*Autosomal dominant with variable penetrance.<ref name=pmid25093518/>
*Autosomal dominant with variable penetrance.<ref name=pmid25093518/>
*Majority (60-70%) are ''de novo'' mutations.<ref name=pmid25093518/>
*Majority (60-70%) are ''de novo'' mutations.<ref name=pmid25093518/>
*May be treated with a mTOR inhibitor,<ref name=pmid23413089>{{Cite journal  | last1 = Pirson | first1 = Y. | title = Tuberous sclerosis complex-associated kidney angiomyolipoma: from contemplation to action. | journal = Nephrol Dial Transplant | volume = 28 | issue = 7 | pages = 1680-5 | month = Jul | year = 2013 | doi = 10.1093/ndt/gft009 | PMID = 23413089 }}</ref> e.g. [[everolimus]].


==Associations==
==Associations==

Revision as of 04:22, 24 January 2016

Micrograph showing a renal angiomyolipoma, as may be seen in tuberous sclerosis. H&E stain. (WC/KGH)

Tuberous sclerosis, also tuberous sclerosis complex (abbreviated TSC), is an autosomal dominant syndrome associated with an increased risk of hamartomas and some risk increase for malignant tumours.

Historically described as:[1]

  1. Epilepsy.
  2. Mental retardation.
  3. Adenoma sebaceum (angiofibromas).

General

  • Autosomal dominant with variable penetrance.[2]
  • Majority (60-70%) are de novo mutations.[2]
  • May be treated with a mTOR inhibitor,[3] e.g. everolimus.

Associations

Pathologic:

Note:

  • The same genes (TSC1, TSC2) are implicated in PEComas.
  • Renal lesions are seen in ~60% of patients.[4]

Mnemonic SALSA HEART:[6]

Genes

  • TSC1.[8]
  • TSC2.[9]
    • Some evidence to suggest it is more often implicated in malignant tumours (than TSC1).[10]
    • TSC2 mutations have a higher prevalence (than TSC1 mutations) and are considered more aggressive.[4]

Notes:

  • The proteins (hamartin and tuberin) are expressed in a wide variety of tissues.[11]

Incidence

~1 in 10,000 population.[1][10]

See also

References

  1. 1.0 1.1 URL: http://emedicine.medscape.com/article/1177711-overview. Accessed on: 13 February 2011.
  2. 2.0 2.1 2.2 2.3 2.4 Guo, J.; Tretiakova, MS.; Troxell, ML.; Osunkoya, AO.; Fadare, O.; Sangoi, AR.; Shen, SS.; Lopez-Beltran, A. et al. (Nov 2014). "Tuberous Sclerosis-associated Renal Cell Carcinoma: A Clinicopathologic Study of 57 Separate Carcinomas in 18 Patients.". Am J Surg Pathol 38 (11): 1457-67. doi:10.1097/PAS.0000000000000248. PMID 25093518.
  3. Pirson, Y. (Jul 2013). "Tuberous sclerosis complex-associated kidney angiomyolipoma: from contemplation to action.". Nephrol Dial Transplant 28 (7): 1680-5. doi:10.1093/ndt/gft009. PMID 23413089.
  4. 4.0 4.1 4.2 4.3 4.4 Rakowski SK, Winterkorn EB, Paul E, Steele DJ, Halpern EF, Thiele EA (November 2006). "Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors". Kidney Int. 70 (10): 1777–82. doi:10.1038/sj.ki.5001853. PMID 17003820.
  5. Grajkowska, W.; Kotulska, K.; Jurkiewicz, E.; Roszkowski, M.; Daszkiewicz, P.; Jóźwiak, S.; Matyja, E. (2011). "Subependymal giant cell astrocytomas with atypical histological features mimicking malignant gliomas.". Folia Neuropathol 49 (1): 39-46. PMID 21455842.
  6. URL: http://www.usmle-forums.com/usmle-step-1-mnemonics/303-tuberous-sclerosis.html. Accessed on: 20 October 2011.
  7. URL: http://dermatology-s10.cdlib.org/1611/articles/3_2009-11-17/batra.html. Accessed on: 18 February 2012.
  8. Online 'Mendelian Inheritance in Man' (OMIM) 605284
  9. Online 'Mendelian Inheritance in Man' (OMIM) 191092
  10. 10.0 10.1 Al-Saleem T, Wessner LL, Scheithauer BW, et al. (November 1998). "Malignant tumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex". Cancer 83 (10): 2208–16. PMID 9827727.
  11. Johnson, MW.; Kerfoot, C.; Bushnell, T.; Li, M.; Vinters, HV. (Mar 2001). "Hamartin and tuberin expression in human tissues.". Mod Pathol 14 (3): 202-10. doi:10.1038/modpathol.3880286. PMID 11266527.